Skip to content

Geron GERN Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.07B+15.4%
Incyte logo
IncyteINCY
$5.62B+53.3%
Immunome logo
ImmunomeIMNM
$588.69M+91.7%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$41.62M-80.6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$524M-1.3%
Celcuity logo
CelcuityCELC
$53.53M-38.2%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's total equity?
Geron (GERN) reported total equity of $229.11M in Q1 2026.
How has Geron's total equity changed year-over-year?
Geron's total equity decreased by 14.6% year-over-year, from $268.24M to $229.11M.
What is the long-term trend for Geron's total equity?
Over 5 years (2020 to 2025), Geron's total equity has grown at a 1.4% compound annual growth rate (CAGR), from $210.95M to $225.87M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.